On December 1, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that it will host an investor event featuring members of the Kura management team and investigators from KOMET-001, a Phase 1/2 clinical trial of ziftomenib, the Company’s potent and selective menin inhibitor (Press release, Kura Oncology, DEC 1, 2022, View Source [SID1234624675]). The in-person investor event and live webcast will take place on Saturday, December 10, 2022, at 11:15 a.m. CT / 12:15 p.m. ET, following an oral presentation of updated data from the KOMET-001 trial at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in New Orleans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To register for the webcast in advance, please sign up here. The live webcast will also be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available shortly after the event.